Home › Wilms Tumor › Ohio › Cincinnati
Wilms Tumor clinical trials in Cincinnati, OH
4 studies for Wilms Tumor are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center (Data collection only), Cincinnati
About Wilms Tumor
Wilms' Tumor (or Nephroblastoma) is a rare type of cancer that affects one or both kidneys. Find a list of symptoms and treatments associated
More about Wilms Tumor on MedlinePlus
Wilms Tumor trials in other cities
- Washington, DC7 studies
- Memphis, TN6 studies
- Atlanta, GA5 studies
- Boston, MA4 studies
- Chicago, IL4 studies
- St. Louis, MO4 studies
- Mountain View, CA4 studies
- New York City, NY4 studies
- Los Angeles, CA4 studies
- Aurora, CO4 studies
- Houston, TX4 studies
- Philadelphia, PA4 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer35 studies
- Cancer (all types)28 studies
- Breast Cancer25 studies
- Heart Failure24 studies
- Colorectal Cancer21 studies
- Obesity20 studies
- Metastatic Cancer20 studies
- Acute Myeloid Leukemia20 studies
- Lung Cancer19 studies
- Ovarian Cancer19 studies
- Prostate Cancer18 studies
- Melanoma17 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.